Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies
Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.
Sleep-Wake Disorders | 26/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy